Hong Kong MDACS GN-00 Update: Why Injectable Dermal Fillers Are Now Medical Devices

What Changed on 13 May 2026

On 13 May 2026, Hong Kong's Medical Device Division (MDD) — the regulatory body within the Department of Health that administers the Medical Device Administrative Control System (MDACS) — published an update to GN-00, the foundational guidance document that defines key terms used across the entire MDACS framework.

The revised document, issued as GN-00:2026-1(E), records three specific changes in its revision history:

1. Revision to Clause 2.38 — the clause that defines what qualifies as a medical device under MDACS
2. Addition of Appendix 1 — a new appendix listing specific product categories treated as medical devices
3. Updated document format — an administrative change with no regulatory impact

The substantive change is the interaction between the revised Clause 2.38(b) and the newly added Appendix 1. Clause 2.38 now states that a medical device includes items specified by the MDD for the purposes of the definition. Appendix 1 lists those items — and the first entry is "injectable dermal fillers or mucous membrane fillers."

In practical terms: injectable dermal fillers are now expressly treated as medical devices under Hong Kong's MDACS framework. The update took effect immediately upon publication.

Why This Update Was Necessary

The Regulatory Grey Area Before GN-00:2026-1

Before this update, injectable dermal fillers sat in a regulatory grey area in Hong Kong. The product category did not fit neatly into any single regulatory framework:

• Not clearly medical devices: Dermal fillers marketed purely for cosmetic or aesthetic purposes — wrinkle correction, lip augmentation, facial contouring — lacked a recognized medical purpose under Hong Kong's device definition. MDACS listing applications for cosmetic-only injectables were typically not accepted by the MDD.
• Not clearly pharmaceuticals: While injectable products are generally assumed to be pharmaceutical products under the Pharmacy and Poisons Ordinance (Cap. 138), many dermal fillers — particularly hyaluronic acid-based products — could not easily meet pharmaceutical registration requirements because they lacked a pharmacological mode of action.
• Not cosmetics: Topical cosmetics are regulated under the Consumer Goods Safety Ordinance (Cap. 456), but injectable products fall outside the scope of cosmetics regulation entirely. There is no separate aesthetic injectables category in Hong Kong law.

The result was commercial uncertainty. Products could be delayed at customs, rejected for listing, or forced into inappropriate regulatory pathways. Some companies relied on informal correspondence or overseas approvals (such as CE marking under EU MDR or NMPA approval in Mainland China) to support market access — a strategy that became increasingly risky as the MDD and the Pharmacy and Poisons Board tightened classification guidance.

The April 2026 Pharmacy and Poisons Board Clarification

Three weeks before the GN-00 update, on 23 April 2026, Hong Kong's Pharmacy and Poisons Board endorsed updated guidance on the classification of products as "pharmaceutical products" under the Pharmacy and Poisons Ordinance (Cap. 138). This clarification reinforced that products intended for human parenteral injection are, in general, regarded as pharmaceutical products.

The two updates together created a coherent regulatory position:

• Default rule: Injectable products are presumed to be pharmaceutical products under Cap. 138.
• Specific exception: Where the MDD has identified a product category as a medical device — as it has now done for injectable dermal fillers via GN-00 Appendix 1 — that category can be regulated under MDACS.

This dual-framework approach gives the MDD the authority to carve out specific injectable product types for medical device regulation, even while the general rule treats injectables as pharmaceuticals.

How Dermal Fillers Fit the Medical Device Definition

The GN-00 Definition of a Medical Device

Under Clause 2.38 of GN-00, a medical device is defined as any instrument, apparatus, implement, machine, appliance, implant, in vitro reagent or calibrator, software, material, or other similar or related article intended by the manufacturer to be used, alone or in combination, for one or more of the specific purposes set out in the definition, and which does not achieve its primary intended action in or on the human body by pharmacological, immunological, or metabolic means.

The updated Clause 2.38(b) now extends this definition to include items specified by the MDD — that is, products listed in Appendix 1.

Why Dermal Fillers Qualify as Medical Devices

Injectable dermal fillers meet the medical device definition on several grounds:

• Physical action: Hyaluronic acid-based fillers, calcium hydroxylapatite suspensions, poly-L-lactic acid particles, and other common filler materials work primarily by physical means — providing volume, structural support, and tissue augmentation. The primary mode of action is mechanical, not pharmacological.
• Intended purpose: Even when the stated purpose is cosmetic (e.g., wrinkle correction, lip enhancement, facial volume restoration), the product modifies body structure or anatomy through injection into tissue. Hong Kong's updated definition now captures this regardless of whether the indication is medical or aesthetic.
• International precedent: The EU classifies dermal fillers as Class III medical devices under MDR Annex VIII (Rules 7 and 8), including those without a medical purpose under Annex XVI. The US FDA regulates dermal fillers as prescription medical devices (product codes LMH and PKY). The UK MHRA is moving to reclassify all dermal fillers under medical device regulations. Hong Kong's update aligns with this global consensus.

What "Treated As" Means in Practice

The GN-00 language — items "treated as" medical devices — is significant. It does not mean dermal fillers have been reclassified from one category to another. Rather, it means the MDD has determined that these products fall within the scope of MDACS and can be listed as medical devices, even where classification was previously uncertain.

For manufacturers, this means:

• Dermal fillers can now be submitted for MDACS listing through the standard device listing pathway
• The MDD will accept listing applications for dermal fillers with cosmetic-only indications
• Products previously rejected for MDACS listing due to lack of a medical purpose may now qualify
• The entire product configuration (filler material, syringe, needle) should be covered under a single legal manufacturer

Comparison With International Classification Frameworks

Hong Kong's approach is broadly consistent with these jurisdictions. The key difference is that Hong Kong's MDACS remains a voluntary listing system with no government fees, whereas the EU, US, and China require mandatory registration with associated costs and timelines.

What the GN-00 Update Means for Your Regulatory Strategy

For Manufacturers Already Selling Dermal Fillers in Hong Kong

If your dermal filler products are currently on the Hong Kong market without MDACS listing — perhaps marketed through distributors or under informal classification arrangements — you should:

1. Assess your current classification basis: Determine whether your product was imported under a pharmaceutical, cosmetic, or informal device classification. If the basis is uncertain or relies on historical practice, the GN-00 update provides an opportunity to regularize.
2. Evaluate MDACS listing: The updated framework now provides a clear pathway. Listing enhances market credibility, supports distributor confidence, and is required for participation in Department of Health tenders under Stage C procurement rules (effective since March 2026).
3. Review your LRP arrangement: If you do not already have a Local Responsible Person appointed in Hong Kong, you will need one to submit and maintain an MDACS listing. LRP services from established providers such as Pure Global start at approximately US$2,000/year for a Class I/II listing, with government fees currently at zero.

For Manufacturers Planning Hong Kong Market Entry

The GN-00 update simplifies your market access planning:

1. Confirm classification: Injectable dermal fillers are medical devices under MDACS. You no longer need to pursue pharmaceutical registration under Cap. 138 (unless your product contains a pharmacologically active substance that constitutes its primary mode of action).
2. Prepare technical documentation: You will need a STED-format technical dossier demonstrating conformity with the Essential Principles of Safety and Performance, including evidence from a recognized reference country approval (FDA, EU CE mark, Health Canada, TGA Australia, PMDA Japan, NMPA China, MFDS South Korea, or HSA Singapore).
3. Appoint an LRP: Your LRP will submit the listing application via the Medical Device Information System (MDIS), manage communications with the MDD, and handle post-market obligations including adverse event reporting.

For Importers and Distributors

If you are a Hong Kong-based importer or distributor handling dermal filler products:

1. Verify that your suppliers have MDACS listing or are pursuing it: Unlisted products face increasing risk of customs delays and non-clearance.
2. Ensure your trader listing is current: MDACS requires importers and distributors to be listed. Check that your listing is active and up to date.
3. Prepare for enhanced scrutiny: The April 2026 Pharmacy and Poisons Board clarification and the May 2026 GN-00 update together signal heightened regulatory attention to injectable products. Compliance gaps are more likely to be identified.

Timeline and Key Dates

What to Do Next

The GN-00 update creates a defined pathway for dermal filler regulation in Hong Kong. Companies that act now — by pursuing MDACS listing, appointing a qualified LRP, and ensuring their technical documentation is aligned with MDACS requirements — will be better positioned for both current market access and the eventual transition to mandatory statutory regulation under the planned Centre for Medical Products Regulation (CMPR).

For specific guidance on the MDACS listing process, LRP selection, technical documentation requirements, and cost planning, see our companion guides:

• Hong Kong Medical Device Registration: MDACS and LRP Guide
• Hong Kong Medical Device Registration Cost and LRP Pricing 2026